Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 6/2006

01-06-2006 | Review Article

Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease

Authors: Dr T. Heinen-Kammerer, H. Rulhoff, S. Nelles, R. Rychlik

Published in: Clinical Drug Investigation | Issue 6/2006

Login to get access

Abstract

When evaluating the added therapeutic value of a drug, evidence of greater overall benefit or at least an add-on benefit is increasingly being required. Therefore, cost-effectiveness in addition to clinical efficacy is an important consideration. The efficacy of a drug must be examined on the basis of clinical trials by measuring specific parameters that are affected by the drug (for example blood pressure with antihypertensive treatment). Today not only efficacy but also patient-relevant changes (patient benefits) must be demonstrated for a drug, often by measuring quality of life. In order to evaluate the benefit of monotherapy with the N-methyl-D-aspartate antagonist memantine in the management of moderate to severe Alzheimer’s disease, a systematic literature review was conducted. The results showed a benefit for memantine in comparison with placebo in terms of a decrease in nursing care, a delay in care dependency and a delay in admission to nursing homes. In addition, an increase in quality of life has been observed.
Literature
1.
Arzneimittelkommission der deutschen Ärzteschaft: Empfehlungen zur Therapie der Demenz. 3. Auflage 2004
2.
Leber P. Guidelines for the clinical evaluation of antidementia drugs, 1st draft. Rockville (MD): US Food and Drug Administration, 1990
3.
Wimo A, Winblad B, Stöffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 2003; 21(5): 327–40PubMedCrossRef
4.
Rychlik R, Wertheimer A, Ruschesbap H, et al. Policy decision making and outcomes research in drug utilization. J Public Health 2005; 13: 257–64CrossRef
5.
Paul JE, Trueman P: ‘Fourth hurdle reviews’, NICE, and database applications. Pharmacoepidemiol Drug Saf 2001; 10(5): 429–438PubMedCrossRef
6.
Ministerie van Volksgezondheit en Sport (VWS): Medicines’ policy in the Netherlands. International Publication Series Health, Welfare and Sport no 15.2002 [online]. Available from URL: http://​www.​minvws.​nl/​ [Accessed 2006 Mar 29]
7.
Zentner A, Velasco-Garrido M, Busse R. Methods for the comparative evaluation of Pharmaceuticals. In: Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information (Dahta@Dimdi), 1. Auflage 2005. Available from URL: http://​www.​dimdi.​de [Accessed 2006 Mar 29]
8.
Gray JAM. Evidence-based healthcare. New York: Churchill Livingstone, 1997
9.
Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate to severe Alzheimer’s disease. N Engl J Med 2003; 348(14): 1333–41PubMedCrossRef
10.
Winblad B, Poritis N. Memantine in severe dementia: results of the M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–46PubMedCrossRef
11.
Marder K. Memantine approved to treat moderate to severe AD. Curr Neurol Neurosci Rep 2003; 4: 349–50CrossRef
12.
13.
Doody R, Wirth Y, Schmitt F, et al. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 18: 227–32PubMedCrossRef
14.
Farlow MR. NMDA receptor antagonists: a new therapeutic approach for Alzheimer’s disease. Geriatrics 2004; 59(6): 22–7PubMed
15.
Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer’s disease. Clin Ther 2004; 26: 615–30PubMedCrossRef
16.
17.
Danysz W, Parsons CG, Möbius HJ, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2000; 2: 85–98CrossRef
18.
Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–22PubMedCrossRef
19.
Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist — a review of preclinical data. Neuropharmacology 1999; 38(6): 735–67PubMedCrossRef
20.
Reisberg B, Doody R, Stöffler A, et al. Is memantine a breakthrough in the treatment of moderate to severe Alzheimer’s disease? Expert Opin Pharmacother 2003; 4(10): 1857–60CrossRef
21.
Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005; 20: 459–64PubMedCrossRef
22.
Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14PubMedCrossRef
23.
Ikeda M, Fukuhara R, Shigenobu K, et al. Dementia associated mental and behavioural disturbances in elderly people in the community: findings from the first Nakayama study. J Neurol Psychiatry 2004; 75; 146–8
24.
25.
Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–7PubMedCrossRef
26.
Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006; 21: 175–81PubMedCrossRef
27.
28.
Falke E, Nissanov J, Mitchell TW, et al. Subicular dendritic arborization in Alzheimer’s disease correlates with neurofibrillary tangle density. Am J Pathol 2003; 163: 1615–21PubMedCrossRef
29.
Caro J, Ward A, Ishak K, et al. To what degree does cognitive impairment in Alzheimer’s disease predict dependence of patients on caregivers? BMC Neurol 2002; 2: 6PubMedCrossRef
30.
Ávila R, Bottino CMC, Carvalho IAM, et al. Neuropsychological rehabilitation of memory deficits and activities of daily living in patients with Alzheimer’s disease: a pilot study. Braz J Med Biol Res 2004; 37(11): 1721–9PubMedCrossRef
31.
The European Agency for the Evaluation of Medicinal Products. Commitee for Propriety Medicinal Products (CPMP). Note for guidance on medicinal products in the treatment of Alzheimer’s disease. CMP/EWP/553/95; London: CPMP, 1997 Sep
32.
Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16(7): 653–66PubMedCrossRef
33.
The European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products (CPMP/EWP/ 553/95 corrected). Note for guidance on medicinal products in the treatment of Alzheimer’s disease [online]. London: CPMP, 1997 Sep. Available from URL: http://​www.​eudra.​org/​emea.​html [Accessed 2006 Mar 29]
34.
Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005; 331(7512): 321–7PubMedCrossRef
35.
Reisberg B, Doody R, Stöffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63(1): 49–54PubMedCrossRef
36.
Launois R, Guilhaume C, Francois C, et al. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer’s disease in Norway. 6th International Conference on Alzheimer’s and Parkinson’s Diseases; 2003 May 8–12; Seville, Spain
37.
38.
Kunz R, Ollenschläger G, Raspe H, et. al. Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis. Deutscher Ärzte-Verlag Köln: 2000
39.
Moher D, Schulz KF, Altman DG, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191–4PubMedCrossRef
40.
Des Jarlais DC, Lyles C, Crepaz N, et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND Statement. Am J Public Health 2004 Mar; 94(3): 361–6PubMedCrossRef
41.
Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidece based medicine: what it is and what it isn’t. BMJ 1996; 312: 71–2PubMedCrossRef
42.
Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 87–93PubMedCrossRef
43.
Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer disease. Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, UK. Health Technol Assess 2006; 10: 1
44.
Antonanzas F, Badenas J, Francois C, et al. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer’s disease in Spain. Value Health 2003; 6(6): 765CrossRef
45.
46.
Feret B, Dicks R. Focus on… memantine. An oral NMDA antagonist for the treatment of moderate-to-severe Alzheimer’s disease. Formulary 2004; 39: 91–103
47.
Ferris SH. Evaluation of memantine for the treatment of AD. Expert Opinion 2003; 4(12): 2305–13CrossRef
48.
49.
Francois C, Sintonen H, Sulkava R, et al. Cost effectiveness of memantine in moderately severe to severe AD: a Markov model in Finland. Clin Drug Invest 2004; 24(7): 373–84CrossRef
50.
Gysling E. Memantin. Pharma-Kritik 2003; 13: 49–50
51.
Hellwig B. Memantin zur Behandlung der Alzheimer-Demenz. Deutsche Apothekerzeitung 2002; 142(12): 44–7
52.
Ho Y, Chagan L. Memantine: a new treatment option for patients with moderate to severe Alzheimer’s disease. P&T 2004; 29(3): 162–5
53.
Jain KK. Evaluation of memantine for neuroprotection in dementia. Drug Evaluation 2000; 9(6): 1397–406
54.
Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease. Drugs Aging 2004; 21(9): 607–20PubMedCrossRef
55.
Koch HJ, Szecsey A, Haen E. NMDA-antagonism (memantine): an alternative pharmacological therpeutic principle. Curr Pharm Des 2004; 10: 253–9PubMedCrossRef
56.
Livingston G, Katona C. The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004; 19: 919–25PubMedCrossRef
57.
Möbius HJ. Memantine: update on the current evidence. Int J Geriatr Psychiatry 2003; 18: 47–54CrossRef
58.
Möbius HJ, Stöffler A, Graham SM. Memantine hydrochloride. Pharmacological and clinical profile. Drugs Today 2004; 40(8): 685–95PubMedCrossRef
59.
Molinuevo JL, Garcia-Gi V, Villar A. Memantine: an antigluta-matergic option for dementia. Am J Alzheimer’s Dis Other Demen 2004; 19(1): 10–8CrossRef
60.
National Horizon Scanning Centre: Memantine for Alzheimer’s disease and vascular dementia. Horizon Scanning Review 2001
61.
Anonymous. Memantine for dementia? Drugs Therap Bull 2003; 41 (10): 73-6
62.
Anonymous. Memantine: poor evaluation and uncertain benefit in Alzheimer’s disease. Rev Prescrire 2003; 12 (68): 203-5
63.
Perras C. Memantine for treatment of moderate to severe Alzheimer’s disease. Issues in emerging health technologies CCOHTA 2004; 64 March
64.
Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate to severe Alzheimer’s disease. Pharmacoeconomics 2005; 23(2): 193–206PubMedCrossRef
65.
Porsteinsson AP, Ismail MS. Memantine — a novel therapeutic option for Alzheimer’s disease. Todays Therap Trends 2004; 22819: 17–28
66.
Rive B, Vercelletto M, Damier FD, et al. Memantine enhances autonomy in moderate to severe AD. Int J Geriatr Psychiatry 2004; 19: 458–64PubMedCrossRef
67.
Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004 Dec; 2(4): 303–12PubMedCrossRef
68.
Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer’s disease and other neurodegenerative disorders: memantine, a new hope. Pharmacol Res 2005; 51: 1–17PubMedCrossRef
69.
70.
Winblad B, Jelic V. Treating the full spectrum of dementia with memantine. Int J Geriatr Psychiatry 2003; 18: 41–6CrossRef
71.
Arnold K, Lehfeld H, Mösler T, et al. Scale properties of the D-scale in severe dementia [abstract]. Neurobiol Aging 1998; 19Suppl. 4S: 30
Metadata
Title
Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease
Authors
Dr T. Heinen-Kammerer
H. Rulhoff
S. Nelles
R. Rychlik
Publication date
01-06-2006
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 6/2006
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200626060-00001

Other articles of this Issue 6/2006

Clinical Drug Investigation 6/2006 Go to the issue

Original Research Article

Long-Term Safety of Intravenous Ibandronic Acid for Up to 4 Years in Metastatic Breast Cancer

Original Research Article

Impact of Influenza Treatment with Oseltamivir on Health, Sleep and Daily Activities of Otherwise Healthy Adults and Adolescents

Original Research Article

Use of Unfractionated Heparin and a Low-Molecular-Weight Heparin following Thrombolytic Therapy for Acute ST-Segment Elevation Myocardial Infarction

Original Research Article

Ciprofloxacin Bioavailability is Enhanced by Oral Co-Administration with Phenazopyridine

Case Report

Cholelithiasis and Thrombosis of the Central Retinal Vein in a Renal Transplant Recipient Treated with Cyclosporin

Original Research Article

Montelukast Decreases Plasma Endothelin-1 and Serum Eosinophil Cationic Protein Levels in Paediatric Atopic Asthma